全球最主要的两款GLP-1减重药的竞争正在进入白热化。美国当地时间5月11日,礼来在《新英格兰医学杂志》(NEJM)上最新发表了GLP/GLP-1双受体激动剂替尔泊肽与GLP-1单受体激动剂司美格鲁肽的一项“头对头”对照研究的详细结果。数据显示,替尔泊肽与司美格鲁肽相比实现了1.47倍的相对体重减轻。这项被命名为SURMOUNT-5的三期大规模临床研究旨在评估在肥胖或伴有至少一种合并症(如高血压、...
Source Link全球最主要的两款GLP-1减重药的竞争正在进入白热化。美国当地时间5月11日,礼来在《新英格兰医学杂志》(NEJM)上最新发表了GLP/GLP-1双受体激动剂替尔泊肽与GLP-1单受体激动剂司美格鲁肽的一项“头对头”对照研究的详细结果。数据显示,替尔泊肽与司美格鲁肽相比实现了1.47倍的相对体重减轻。这项被命名为SURMOUNT-5的三期大规模临床研究旨在评估在肥胖或伴有至少一种合并症(如高血压、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.